SABS Stock Analysis: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$4.09
0.29 (7.63%)
▲
5d:
+9.36%
30d:
+9.65%
90d:
+2.76%
BUY
MODERATE Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SABS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SABS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $4.09, which is considered extended relative to its 30-day fair value range of $3.62 to $3.94.
Technical Outlook: Technically, SABS is in a downtrend. Immediate support is located at $3.41, while resistance sits at $4.45. The stock is showing strong short-term momentum, up 7.6% recently.
Market Sentiment: SABS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+132.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SABS is in a downtrend. Immediate support is located at $3.41, while resistance sits at $4.45. The stock is showing strong short-term momentum, up 7.6% recently.
Market Sentiment: SABS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+132.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.62 -
$3.94
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.6%)
- BULLISH: Trading 132.3% below Wall St target ($9.50)
Trading Range Analysis
30-Day Trading Range
$3.62 -
$3.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.41
Resistance Level
$4.45
Current Trend
Downtrend
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.39
Wall Street Target
$9.50
(+132.3%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: May 08, 2026 7:09 AM ET
Data refreshes hourly during market hours. Next update: 8:09 AM
Data refreshes hourly during market hours. Next update: 8:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 50 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 63 BUY |
